Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 1/20 | 0.61 |
| ▸ | SKP1 | P63208 | 1/20 | 0.61 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.61 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.60 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.57 |
| ▸ | KDM1A | O60341 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 4/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | PIM1 | P11309 | 1/20 | 0.50 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.50 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.49 |
| ▸ | ME3 | Q16798 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23500781 | 0.92 | CKS1B (0.56) | CKS1BSKP1SKP2GPR119KCNA3 | |
| SCHEMBL15222937 | 0.92 | CKS1B (0.56) | CKS1BSKP1SKP2GPR119KCNA3 | |
| SCHEMBL2881659 | 0.90 | CKS1B (0.55) | CKS1BSKP1SKP2GPR119KCNA3 | |
| SCHEMBL383106 | 0.88 | USP2 (0.56) | CKS1BSKP1SKP2GPR119KCNA3 | |
| SCHEMBL23841095 | 0.88 | GPR119 (0.59) | CKS1BSKP1SKP2GPR119KCNA3 | |
| SCHEMBL3130708 | 0.88 | CKS1B (0.52) | CKS1BSKP1SKP2GPR119KCNA3 | |
| SCHEMBL32665409 | 0.88 | ME3 (0.54) | CKS1BSKP1SKP2GPR119KCNA3 | |
| SCHEMBL3865823 | 0.87 | KDM1A (0.52) | CKS1BSKP1SKP2GPR119KCNA3 | |
| SCHEMBL1456142 | 0.86 | CKS1B (0.54) | CKS1BSKP1SKP2GPR119KCNA3 | |
| SCHEMBL5216885 | 0.86 | CHRM4 (0.53) | CKS1BSKP1SKP2GPR119KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662206-A1 | GSPT1 DEGRADER COMPOUNDS | Captor Therapeutics S.A. (PL) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024165577-A1 | GSPT1 DEGRADER COMPOUNDS | CAPTOR THERAPEUTICS S.A. (PL) | 2024-08-15 | — | — | WO | disclosed |
| EP-3725787-B1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | REGENACY PHARMACEUTICALS INC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230348389-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | REGENACY PHARMACEUTICALS LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230348389-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | REGENACY PHARMACEUTICALS LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-11702389-B2 | Piperidine derivatives as HDAC1/2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702389-B2 | Piperidine derivatives as HDAC1/2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210179559-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2021-06-17 | — | — | US | disclosed |
| US-10968180-B2 | Piperidine derivatives as HDAC1/2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2021-04-06 | — | — | US | disclosed |
| EP-3292113-B1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | REGENACY PHARMACEUTICALS LLC (US) | 2020-07-08 | — | — | EP | disclosed |
| US-10239837-B2 | Piperidine derivatives as HDAC1/2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180022702-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | ACETYLON PHARMACEUTICALS, INC. | 2018-01-25 | — | — | US | disclosed |
| US-20180022702-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | ACETYLON PHARMACEUTICALS, INC. | 2018-01-25 | — | — | US | disclosed |
| US-20170369441-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2017-12-28 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-9790180-B2 | Piperidine derivatives as HDAC1/2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790180-B2 | Piperidine derivatives as HDAC1/2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160168093-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2016-06-16 | — | — | US | disclosed |
| US-20160168093-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168093-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | HDAC1, HDAC2, HDAC10 | CKS1B 771/4885SKP1 1267/4885SKP2 103/4885 |
| US-20170369441-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | HDAC1, HDAC2, HDAC10 | CKS1B 771/4885SKP1 1267/4885SKP2 103/4885 |
| US-20210179559-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | HDAC1, HDAC2, HDAC10 | CKS1B 771/4885SKP1 1267/4885SKP2 103/4885 |
| US-11702389-B2 | Piperidine derivatives as HDAC1/2 inhibitors | HDAC1, HDAC2, HDAC10 | CKS1B 771/4885SKP1 1267/4885SKP2 103/4885 |
| US-20230348389-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | HDAC1, HDAC2, HDAC10 | CKS1B 771/4885SKP1 1267/4885SKP2 103/4885 |
| US-10968180-B2 | Piperidine derivatives as HDAC1/2 inhibitors | HDAC1, HDAC2, HDAC10 | CKS1B 771/4885SKP1 1267/4885SKP2 103/4885 |
| US-10239837-B2 | Piperidine derivatives as HDAC1/2 inhibitors | HDAC1, HDAC2, HDAC10 | CKS1B 771/4885SKP1 1267/4885SKP2 103/4885 |
| US-20180022702-A1 | PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS | HDAC1, HDAC2, HDAC10 | CKS1B 771/4885SKP1 1267/4885SKP2 103/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | CKS1B 239/4885SKP1 2240/4885SKP2 2256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.